ImmunoGen Ownership
ImmunoGen has a total of 279.35 Million outstanding shares. The majority of ImmunoGen outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in ImmunoGen to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in ImmunoGen. Please pay attention to any change in the institutional holdings of ImmunoGen as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as ImmunoGen in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of ImmunoGen, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
ImmunoGen |
ImmunoGen Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.28. ImmunoGen had not issued any dividends in recent years. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. To learn more about ImmunoGen call Mark Enyedy at 781 895 0600 or check out https://www.immunogen.com.ImmunoGen Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunoGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunoGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmunoGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
White Lauren over a year ago Acquisition by White Lauren of 19519 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 27788 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 6792 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 166725 shares of ImmunoGen subject to Rule 16b-3 | ||
Richard Wallace over a year ago Exercise or conversion by Richard Wallace of 10000 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 158641 shares of ImmunoGen subject to Rule 16b-3 | ||
White Lauren over a year ago Acquisition by White Lauren of 295975 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Acquisition by Theresa Wingrove of 23400 shares of ImmunoGen subject to Rule 16b-3 |
ImmunoGen Outstanding Bonds
ImmunoGen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ImmunoGen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ImmunoGen bonds can be classified according to their maturity, which is the date when ImmunoGen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nu Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nu Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nu Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nu Holdings to buy it.
The correlation of Nu Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nu Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nu Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nu Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |